Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Amino Acids
2015 Dec 01;4712:2647-58. doi: 10.1007/s00726-015-2057-3.
Show Gene links
Show Anatomy links
Hypomorphic variants of cationic amino acid transporter 3 in males with autism spectrum disorders.
Nava C
,
Rupp J
,
Boissel JP
,
Mignot C
,
Rastetter A
,
Amiet C
,
Jacquette A
,
Dupuits C
,
Bouteiller D
,
Keren B
,
Ruberg M
,
Faudet A
,
Doummar D
,
Philippe A
,
Périsse D
,
Laurent C
,
Lebrun N
,
Guillemot V
,
Chelly J
,
Cohen D
,
Héron D
,
Brice A
,
Closs EI
,
Depienne C
.
???displayArticle.abstract???
Cationic amino acid transporters (CATs) mediate the entry of L-type cationic amino acids (arginine, ornithine and lysine) into the cells including neurons. CAT-3, encoded by the SLC7A3 gene on chromosome X, is one of the three CATs present in the human genome, with selective expression in brain. SLC7A3 is highly intolerant to variation in humans, as attested by the low frequency of deleterious variants in available databases, but the impact on variants in this gene in humans remains undefined. In this study, we identified a missense variant in SLC7A3, encoding the CAT-3 cationic amino acid transporter, on chromosome X by exome sequencing in two brothers with autism spectrum disorder (ASD). We then sequenced the SLC7A3 coding sequence in 148 male patients with ASD and identified three additional rare missense variants in unrelated patients. Functional analyses of the mutant transporters showed that two of the four identified variants cause severe or moderate loss of CAT-3 function due to altered protein stability or abnormal trafficking to the plasma membrane. The patient with the most deleterious SLC7A3 variant had high-functioning autism and epilepsy, and also carries a de novo 16p11.2 duplication possibly contributing to his phenotype. This study shows that rare hypomorphic variants of SLC7A3 exist in male individuals and suggest that SLC7A3 variants possibly contribute to the etiology of ASD in male subjects in association with other genetic factors.
Fig. 1. Identification of missense variants in SLC7A3 in four patients with ASD. a Pedigree of the families and segregation of SLC7A3 variants; m and m/+ denotes male or female individuals carrying one variant in the hemizygous or heterozygous state, respectively. Arrow the index case. Black
symbols individuals diagnosed with ASD; gray symbols patients with undetermined intellectual disability or learning difficulty phenotypes (see details in Supplementary data). b Sequence electropherograms showing the SLC7A3 variants in the hemizygous state in the affected individuals of Families 505 (01, 02), 885, 388, 962 (P), in the heterozygous state in the mother of Family 505 (05) and their absence in an unaffected brother in Family 505 (03) and controls (C). c Alignment of the regions flanking the SLC7A3/CAT-3 missense variant in orthologous proteins showing the conservation of the altered amino acids. d Schematic model of the CAT-3 protein showing the putative location of the amino acid residues altered by the variants
Fig. 2. Subcellular localization and expression of CAT-3 mutants at the plasma membrane in mammalian cells. a Subcellular localization of wild-type and mutant (p.Tyr430Cys, p.Ala331Thr, p.Ser589Thr, p.Ser595Thr) CAT-3 proteins and colocalization with endoplasmic reticulum (ER, marked using anti-calreticulin) observed by confocal microscopy. Scale bar 20 µm. b Representative western blot of WT and mutant CAT-3 protein expression in whole lysates and plasma membranes. Flotillin and Tom20 stainings were used to control membrane protein enrichment and normalize protein load, respectively. c Quantification of WT and mutant CAT-3 proteins present in whole lysates and plasma membranes. The values, obtained from at least three different experiments, were compared with the Mann–Whitney test; *p < 0.05
Fig. 3. Analysis of WT and mutant CAT-3 transport activity, expression and localization in Xenopus laevis oocytes. a Transport of 100 µM [3H]L-arginine for 15 min into oocytes. b Representative Western Blot of WT and mutant CAT-3-EGFP proteins in whole cell lysates and at the plasma membrane. c Quantification of three independent experiments as shown in b, left
columns CAT-3 in total cell lysate, right columns in plasma membrane protein fraction
Fig. 4. Schematic diagram showing the possible consequences of SLC7A3 dysfunction on the mTOR and NO pathways. Reduced availability of intracellular cationic amino acids, including arginine, could decrease NO synthesis and alter NO-mediated signaling (on the left) or negatively affect the mTOR signaling pathway in neurons (on the right)
Amiet,
Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis.
2008, Pubmed
Amiet,
Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis.
2008,
Pubmed
Barrett,
An autosomal genomic screen for autism. Collaborative linkage study of autism.
1999,
Pubmed
Betancur,
Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting.
2011,
Pubmed
Beyer,
Identification of cysteine residues in human cationic amino acid transporter hCAT-2A that are targets for inhibition by N-ethylmaleimide.
2013,
Pubmed
,
Xenbase
Bourgeron,
A synaptic trek to autism.
2009,
Pubmed
Braissant,
L-arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study.
1999,
Pubmed
Bucan,
Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes.
2009,
Pubmed
Chilian,
Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci.
2013,
Pubmed
Closs,
Expression, regulation and function of carrier proteins for cationic amino acids.
2002,
Pubmed
Closs,
Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties.
1997,
Pubmed
,
Xenbase
Closs,
Structure and function of cationic amino acid transporters (CATs).
2006,
Pubmed
Depienne,
Screening for genomic rearrangements and methylation abnormalities of the 15q11-q13 region in autism spectrum disorders.
2009,
Pubmed
Ehninger,
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
2011,
Pubmed
Gauthier,
Mutation screening of FOXP2 in individuals diagnosed with autistic disorder.
2003,
Pubmed
Gilman,
Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses.
2011,
Pubmed
Girirajan,
Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder.
2013,
Pubmed
Glessner,
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes.
2009,
Pubmed
Hafezparast,
Mouse models for neurological disease.
2002,
Pubmed
Heil,
The genetics of Autism Spectrum Disorders--a guide for clinicians.
2013,
Pubmed
Hosokawa,
Cloning and characterization of a brain-specific cationic amino acid transporter.
1997,
Pubmed
Hosokawa,
Neuron-specific expression of cationic amino acid transporter 3 in the adult rat brain.
1999,
Pubmed
Huang,
The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway.
2007,
Pubmed
Huguet,
The genetic landscapes of autism spectrum disorders.
2013,
Pubmed
Iossifov,
De novo gene disruptions in children on the autistic spectrum.
2012,
Pubmed
Iossifov,
The contribution of de novo coding mutations to autism spectrum disorder.
2014,
Pubmed
Ito,
A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain.
1997,
Pubmed
Jeste,
Disentangling the heterogeneity of autism spectrum disorder through genetic findings.
2014,
Pubmed
Jiang,
A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A.
2004,
Pubmed
Junaid,
Proteomic approach for the elucidation of biological defects in autism.
2001,
Pubmed
Jäger,
Differential topochemistry of three cationic amino acid transporter proteins, hCAT1, hCAT2 and hCAT3, in the adult human brain.
2013,
Pubmed
Kidd,
Slit is the midline repellent for the robo receptor in Drosophila.
1999,
Pubmed
Kim,
Transport of cationic amino acids by the mouse ecotropic retrovirus receptor.
1991,
Pubmed
,
Xenbase
Krumm,
A de novo convergence of autism genetics and molecular neuroscience.
2014,
Pubmed
Kumar,
Recurrent 16p11.2 microdeletions in autism.
2008,
Pubmed
Lai,
A forkhead-domain gene is mutated in a severe speech and language disorder.
2001,
Pubmed
Lai,
Autism.
2014,
Pubmed
Leblond,
Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders.
2012,
Pubmed
Levy,
Rare de novo and transmitted copy-number variation in autistic spectrum disorders.
2011,
Pubmed
Murdoch,
Recent developments in the genetics of autism spectrum disorders.
2013,
Pubmed
Nava,
Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders.
2014,
Pubmed
Nava,
De novo mutations in HCN1 cause early infantile epileptic encephalopathy.
2014,
Pubmed
Neale,
Patterns and rates of exonic de novo mutations in autism spectrum disorders.
2012,
Pubmed
Nelson,
Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase.
1995,
Pubmed
Newbury,
FOXP2 is not a major susceptibility gene for autism or specific language impairment.
2002,
Pubmed
Nicholson,
Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines.
1998,
Pubmed
O'Roak,
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations.
2012,
Pubmed
O'Roak,
Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations.
2011,
Pubmed
Perkins,
Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1.
1997,
Pubmed
Pinto,
Functional impact of global rare copy number variation in autism spectrum disorders.
2010,
Pubmed
Sanders,
De novo mutations revealed by whole-exome sequencing are strongly associated with autism.
2012,
Pubmed
Sanders,
Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism.
2011,
Pubmed
Schaaf,
Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders.
2011,
Pubmed
Schaafsma,
Etiologies underlying sex differences in Autism Spectrum Disorders.
2014,
Pubmed
Splawski,
CACNA1H mutations in autism spectrum disorders.
2006,
Pubmed
Srivastava,
Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms.
2014,
Pubmed
Swiech,
Role of mTOR in physiology and pathology of the nervous system.
2008,
Pubmed
Tanda,
Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice.
2009,
Pubmed
Tuchman,
Epilepsy in autism.
2002,
Pubmed
Veenstra-VanderWeele,
Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.
2012,
Pubmed
Veltman,
Understanding variable expressivity in microdeletion syndromes.
2010,
Pubmed
Vékony,
Human cationic amino acid transporter hCAT-3 is preferentially expressed in peripheral tissues.
2001,
Pubmed
,
Xenbase
Wassink,
Evaluation of FOXP2 as an autism susceptibility gene.
2002,
Pubmed
Weiss,
Association between microdeletion and microduplication at 16p11.2 and autism.
2008,
Pubmed
Weitzdoerfer,
Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance.
2004,
Pubmed
Werling,
Sex differences in autism spectrum disorders.
2013,
Pubmed